BIO-RAD LABORATORIES, INC. BIO revenue by segment, product and geography
In its fiscal year ending 2025-12-31, BIO-RAD LABORATORIES, INC. reported revenue across 3 business segments; the largest, Clinical Diagnostics, was $1.56B, 60.5% of the filed sum (+1.6% against the prior period in the same filing).
Reported segment mix
figures as filed · share of the filed sum · change vs the prior period in the same filing- Clinical Diagnostics$1.56B60.5%+1.6% yoy
- Life Science$1.02B39.5%-0.7% yoy
- All Other Segments$00.0%-100.0% yoy
Members sum to the consolidated $2.58B for this period.
- United States$1.02B39.6%-1.8% yoy
- Europe$882M34.1%+5.7% yoy
- Asia Pacific$513M19.9%-1.6% yoy
- Americas$165M6.4%-2.3% yoy
Members sum to the consolidated $2.58B for this period.
- Clinical Diagnostics$364M61.4%+1.9% yoy
- Life Science$229M38.6%0.0% yoy
Change is against the same quarter a year earlier, as reported in the same 10-Q.
Source: SEC DERA Financial Statement and Notes data sets. Dimensional XBRL facts on the business-segment, product/service and geographic axes; the engine keeps the accession of every figure. Descriptive and educational, not advice.
About these figures
Companies tag segment, product and geographic revenue as dimensional XBRL facts in their 10-K and 10-Q filings. The SEC publishes those facts in its DERA Financial Statement and Notes data sets; TrendNalysis ingests each monthly file and serves the facts exactly as filed, keyed to the accession of the filing. Shares are of the filed sum. Where a filer tags more than one breakdown on one axis, the sum exceeds consolidated revenue and no shares are computed; where the members do not add up to the consolidated figure, the residual is stated rather than hidden. Missing is never zero.
Descriptive and educational; not investment advice. Methodology and data lineage.